$VIRX News
Last published 1y ago
- 1y agoVIRXViracta Therapeutics Announces Wind Down of OperationsGlobeNewswireSAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 1y agoVIRXViracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic AlternativesGlobeNewswireSAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 1y agoVIRXViracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from
- 2y agoVIRXViracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell LymphomaGlobeNewswireSAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 2y agoVIRXViracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 2y agoVIRXViracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity
- 2y agoVIRXViracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development PlanGlobeNewswire- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity
- 2y agoVIRXViracta Therapeutics Announces New Employment Inducement GrantsGlobeNewswireSAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients
- 2y agoVIRXViracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerGlobeNewswireSAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients
- 2y agoVIRXViracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswirePresented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) Initial
- 2y agoVIRXViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceGlobeNewswireSAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients
- 2y agoVIRXViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaGlobeNewswire- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in
- 2y agoVIRXViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanGlobeNewswireSAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 2y agoLENZVIRXLENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate ProgressBusiness Wire– LENZ Therapeutics to debut on Nasdaq under the ticker symbol "LENZ" as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase
- 2y agoVIRXViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswireCompleted Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study
- 2y agoVIRXViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialGlobeNewswireAccelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of 2024 SAN DIEGO,
- 2y agoVIRXViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswireSAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 2y agoKYMRNBTXORTXSLN+1INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board DirectorsGlobeNewswireINVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public company and accelerate
- 2y agoVIRXViracta Therapeutics Provides Clinical Update and Outlook for 2024GlobeNewswireSpeed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and
- 2y agoVIRXViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaGlobeNewswireFirst orphan drug designation for Nana-val granted in EBV+ solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Viracta
- 2y agoVIRXViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsGlobeNewswireConfirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher
- 3y agoVIRXViracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireReported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma showing an overall response rate and complete response rate
- 3y agoVIRXViracta Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 3y agoVIRXViracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated CancersGlobeNewswirePreliminary clinical data from patients with relapsed/refractory EBV+ peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study
- 3y agoVIRXViracta Therapeutics to Host R&D Day on October 4, 2023GlobeNewswireSAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 3y agoVIRXViracta Therapeutics Announces New Employment Inducement GrantGlobeNewswireSAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 3y agoVIRXViracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireAchieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in pivotal NAVAL-1 study of Nana-val Prioritized EBV+ diffuse large
- 3y agoVIRXViracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) LymphomaGlobeNewswireResults from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the most aggressive cancers
- 3y agoVIRXViracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical OfficerGlobeNewswireSAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact
- 3y agoVIRXViracta Therapeutics' Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)GlobeNewswireSAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics to Present at the Jefferies Healthcare ConferenceGlobeNewswireSAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceGlobeNewswireSAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program UpdatesGlobeNewswirePivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023 Enrollment into
- 3y agoVIRXViracta Therapeutics Announces Departure of Chief Medical OfficerGlobeNewswireSAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics to Present at the Stifel 2023 Targeted Oncology DaysGlobeNewswireSAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateGlobeNewswirePivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023
- 3y agoVIRXViracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare ConferenceGlobeNewswireSAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceGlobeNewswireSAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell LymphomaGlobeNewswireSAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical ObjectivesGlobeNewswirePartial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into forth dose level is ongoing
- 3y agoVIRXViracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology CongressGlobeNewswireSAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics Announces New Employment Inducement GrantGlobeNewswireSAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 3y agoVIRXViracta Therapeutics Announces New Employment Inducement GrantGlobeNewswireSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,
- 4y agoVIRXViracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical ProgramsGlobeNewswirePivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to Stage 2 now
- 4y agoVIRXViracta Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated cancers, today announced that company leadership is scheduled to present
- 4y agoVIRXViracta Therapeutics Announces New Employment Inducement GrantGlobeNewswireSAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection with the appointment of Mark Rothera as Viracta's new Pres
- 4y agoVIRXViracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and GrowthPR NewswireViracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of Viracta's Board of Directors SAN DIEGO, Sept. 19, 2022 /PRNew
- 4y agoVIRXViracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell LymphomaPR NewswireFirst orphan drug designation granted for Nana-val by the European Commission; fifth globally SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, toda
- 4y agoVIRXViracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated DiseasesPR NewswireSAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr Virus and Associated
- 4y agoVIRXViracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of DirectorsPR NewswireSAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Dire